Prediction and Prevention of Preterm Birth (PREVENT-PTB Study)

Ware Branch

Status

Terminated

Conditions

Preterm Birth

Treatments

Diagnostic Test: PreTRM test

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT03530332

PREVENT-PTB Protocol 1.02

Details and patient eligibility

About

This research study is being done to find out whether a screening blood test can help identify women with an increased risk of preterm birth.

Full description

Preterm birth (PTB) remains the leading cause of neonatal mortality and long-term disability throughout the world. Recently treatments early in pregnancy such as progesterone, cervical support and maternal support have been demonstrated to delay delivery amongst at risk women. Nonetheless, the majority of women who are at risk are not identified using current screening methods.

Women who are 18 years or older, with a singleton pregnancy between 19 5/7 weeks and 20 6/7 weeks gestational age (GA) confirmed by ultrasound prior to enrollment and no history of prior preterm birth (delivery between 16 0/7 weeks and 37 6/7 weeks) will be invited to participate. Women who enroll will be randomized to screening and intervention for those at high risk of PTB or no screening and standard care. All participants will undergo sample collection, but the samples from the group randomized to "no screening' will not be analyzed until the end of the study (post-delivery of all neonates).

Women randomized to the intervention group will be screened using the PreTRM® test (Sera Prognostics, Inc.) at a large tertiary care center. Predicated upon the degree of risk, women will be treated according to a pre-specified algorithm. The outcomes of these women will be compared to a control group of women who do not receive screening at the same tertiary care center.

Enrollment

1,208 patients

Sex

Female

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

Subject is greater than or equal to 18 years of age AND
Uncomplicated singleton intrauterine pregnancy less than 21 weeks estimated gestation AND
No medical contraindications to continuing pregnancy AND
No previous classical cesarean section AND
No known uterine anomaly AND
No history of cervical conization AND
No plan for cesarean section prior to 37 0/7 weeks gestation AND
No plan for induction of labor prior to 37 0/7 weeks gestation AND
Subject has no history of spontaneous preterm delivery AND
No prior PPROM less than 34 weeks AND
Subject has no signs and/or symptoms of preterm labor AND
Subject has intact membranes AND
Subject has not received a blood transfusion during the current pregnancy.

Exclusion Criteria

Subjects who have taken or plan to take progesterone beyond 13 6/7 weeks gestation prior to study enrollment OR
Any other medical conditions that put subject at increased risk of preterm birth in the judgment of the site investigator OR
The subject has a planned cerclage placement for the current pregnancy OR
Previously identified short cervix (less than 2.5 cm by transvaginal ultrasound) prior to enrollment OR
Known major structural fetal anomalies that may shorten pregnancy (e.g., anencephaly, holoprosencephaly, schizencephaly, gastroschisis, omphalocele, congenital diaphragmatic hernia) OR
Known fetal genetic anomalies that are incompatible with life (e.g., trisomy 13 or trisomy 18) OR
The subject has known elevated bilirubin levels (hyperbilirubinemia) OR
The subject has taken or plans to take any of the following medications after the first day of the last menstrual period: Enoxaparin, heparin, heparin sodium, low molecular weight heparin, low dose aspirin OR
A history of allergic reaction to aspirin or 17-OHPC injections OR
Subject does not plan to deliver at an Intermountain Healthcare hospital.